Devices Fill The Lung Space

Interventional pulmonology may be a specialty device market, but its diseases, including COPD, asthma and lung cancer, are enormous and growing.

New companies in emerging markets are fond of saying that they're operating in a field that's like interventional cardiology was, say, 10 or 15 years ago. That's when minimally invasive diagnostic procedures paved the way for minimally invasive device interventions, some of which are now billion dollar markets. Although it's a cliché, the comparison really does ring true for interventional pulmonology, where 6,000 bronchoscopists have long had the tools for the minimally invasive diagnosis of life-threatening disorders, but no therapeutic tools to go along with them.

Ten years ago, the earliest interventional pulmonology companies sprang up; first came Pulmonx Inc. , followed by Broncus Technologies Inc. , Spiration Inc. and Emphasys Medical Inc. These companies saw an opportunity to develop bronchoscopic treatments for emphysema, in the shadow of the National Emphysema Treatment Trial (NETT). NETT was a more than 1,200-patient, five-year, randomized prospective trial sponsored by the National Heart, Lung and Blood Institute in collaboration with the Centers for Medicare and Medicaid Services to determine which, if any, emphysema patients truly benefited from lung volume reduction surgery (LVRS)

More from Archive

More from Medtech Insight

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By 

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.